肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

CLIN CANCER RES：Reparixin联合紫杉醇治疗HER-2阴性转移性乳腺癌

2017-09-20 MedSci MedSci原创

乳腺癌HER-2Reparixin紫杉醇
关注

趋化因子受体1（CXCR1）被认为是乳腺癌干细胞选择性表达的受体。Reparixin是一种在研究中的趋化因子受体1/2（CXCR1/2）抑制剂，在乳腺癌异种移植模型中具有抗乳腺癌干细胞活性。CLIN CANCER RES近期发表了一篇文章，报道了紫杉醇联合Reparixin治疗转移性乳腺癌患者的临床试验结果。

趋化因子受体1（CXCR1）被认为是乳腺癌干细胞选择性表达的受体。Reparixin是一种在研究中的趋化因子受体1/2（CXCR1/2）抑制剂，在乳腺癌异种移植模型中具有抗乳腺癌干细胞活性。CLIN CANCER RES近期发表了一篇文章，报道了紫杉醇联合Reparixin治疗转移性乳腺癌患者的临床试验结果。该临床试验主要研究紫杉醇联合Reparixin治疗的剂量、安全性、药代动力学特征以及对转移性乳腺癌患者肿瘤干细胞的影响。治疗方案为口服Reparixin每天3次，进行3天诱导后接受紫杉醇80mg/m2/周（1，8和15天，周期28天）+Reparixin口服每天3次21/28天。3个剂量队列使用3+3剂量递增设计。额外的患者纳入拓展队列探索Ⅱ期临床试验的推荐剂量，进一步研究联合疗法的药代动力学、安全性及生物学效果。研究结果表明并未出现与研究相关的4-5级不良反应或严重不良反应，Reparixin和紫杉醇之间无相互作用，不会影响各自的药代动力学学特征。反应率为30%，2例患者出现持续反应超过12个月。分子标志分析不能明确对乳腺癌肿瘤干细胞的治疗效果。文章最后认为，每周紫杉醇联合Rep

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1793188, encodeId=2b9b1e93188dd, content=<a href='/topic/show?id=3d9e1532650' target=_blank style='color:#2F92EE;'>#Reparixin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15326, encryptionId=3d9e1532650, topicName=Reparixin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f07c2500133, createdName=12498adam40暂无昵称, createdTime=Mon Jul 02 07:04:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386291, encodeId=07a3138629158, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Sep 22 00:04:00 CST 2017, time=2017-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426841, encodeId=ef4a142684102, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Sep 22 00:04:00 CST 2017, time=2017-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495799, encodeId=9da61495e9933, content=<a href='/topic/show?id=27eb8e1381' target=_blank style='color:#2F92EE;'>#HER-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8713, encryptionId=27eb8e1381, topicName=HER-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b8b9208832, createdName=zhu_jun9840, createdTime=Fri Sep 22 00:04:00 CST 2017, time=2017-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246208, encodeId=f46a24620812, content=文章很好.值得分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Sep 21 06:51:38 CST 2017, time=2017-09-21, status=1, ipAttribution=)]
    2018-07-02 12498adam40暂无昵称

    #Reparixin#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1793188, encodeId=2b9b1e93188dd, content=<a href='/topic/show?id=3d9e1532650' target=_blank style='color:#2F92EE;'>#Reparixin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15326, encryptionId=3d9e1532650, topicName=Reparixin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f07c2500133, createdName=12498adam40暂无昵称, createdTime=Mon Jul 02 07:04:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386291, encodeId=07a3138629158, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Sep 22 00:04:00 CST 2017, time=2017-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426841, encodeId=ef4a142684102, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Sep 22 00:04:00 CST 2017, time=2017-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495799, encodeId=9da61495e9933, content=<a href='/topic/show?id=27eb8e1381' target=_blank style='color:#2F92EE;'>#HER-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8713, encryptionId=27eb8e1381, topicName=HER-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b8b9208832, createdName=zhu_jun9840, createdTime=Fri Sep 22 00:04:00 CST 2017, time=2017-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246208, encodeId=f46a24620812, content=文章很好.值得分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Sep 21 06:51:38 CST 2017, time=2017-09-21, status=1, ipAttribution=)]
    2017-09-22 1249842em09(暂无昵称)

    #转移性#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1793188, encodeId=2b9b1e93188dd, content=<a href='/topic/show?id=3d9e1532650' target=_blank style='color:#2F92EE;'>#Reparixin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15326, encryptionId=3d9e1532650, topicName=Reparixin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f07c2500133, createdName=12498adam40暂无昵称, createdTime=Mon Jul 02 07:04:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386291, encodeId=07a3138629158, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Sep 22 00:04:00 CST 2017, time=2017-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426841, encodeId=ef4a142684102, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Sep 22 00:04:00 CST 2017, time=2017-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495799, encodeId=9da61495e9933, content=<a href='/topic/show?id=27eb8e1381' target=_blank style='color:#2F92EE;'>#HER-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8713, encryptionId=27eb8e1381, topicName=HER-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b8b9208832, createdName=zhu_jun9840, createdTime=Fri Sep 22 00:04:00 CST 2017, time=2017-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246208, encodeId=f46a24620812, content=文章很好.值得分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Sep 21 06:51:38 CST 2017, time=2017-09-21, status=1, ipAttribution=)]
    2017-09-22 gwc384

    #EPA#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1793188, encodeId=2b9b1e93188dd, content=<a href='/topic/show?id=3d9e1532650' target=_blank style='color:#2F92EE;'>#Reparixin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15326, encryptionId=3d9e1532650, topicName=Reparixin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f07c2500133, createdName=12498adam40暂无昵称, createdTime=Mon Jul 02 07:04:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386291, encodeId=07a3138629158, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Sep 22 00:04:00 CST 2017, time=2017-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426841, encodeId=ef4a142684102, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Sep 22 00:04:00 CST 2017, time=2017-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495799, encodeId=9da61495e9933, content=<a href='/topic/show?id=27eb8e1381' target=_blank style='color:#2F92EE;'>#HER-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8713, encryptionId=27eb8e1381, topicName=HER-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b8b9208832, createdName=zhu_jun9840, createdTime=Fri Sep 22 00:04:00 CST 2017, time=2017-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246208, encodeId=f46a24620812, content=文章很好.值得分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Sep 21 06:51:38 CST 2017, time=2017-09-21, status=1, ipAttribution=)]
    2017-09-22 zhu_jun9840

    #HER-2#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1793188, encodeId=2b9b1e93188dd, content=<a href='/topic/show?id=3d9e1532650' target=_blank style='color:#2F92EE;'>#Reparixin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15326, encryptionId=3d9e1532650, topicName=Reparixin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f07c2500133, createdName=12498adam40暂无昵称, createdTime=Mon Jul 02 07:04:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386291, encodeId=07a3138629158, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Sep 22 00:04:00 CST 2017, time=2017-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426841, encodeId=ef4a142684102, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Sep 22 00:04:00 CST 2017, time=2017-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495799, encodeId=9da61495e9933, content=<a href='/topic/show?id=27eb8e1381' target=_blank style='color:#2F92EE;'>#HER-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8713, encryptionId=27eb8e1381, topicName=HER-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b8b9208832, createdName=zhu_jun9840, createdTime=Fri Sep 22 00:04:00 CST 2017, time=2017-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246208, encodeId=f46a24620812, content=文章很好.值得分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Sep 21 06:51:38 CST 2017, time=2017-09-21, status=1, ipAttribution=)]
    2017-09-21 1e10c84am36(暂无匿称)

    文章很好.值得分享

    0

相关资讯

Cancer Res：KDM4酶抑制剂为三阴性乳腺癌患者带来福音

目前研究人员正在研究一种潜在治疗三阴性乳腺癌的新方法，针对特别激进的乳腺癌亚型。三阴性乳腺癌是乳腺癌的一种，顾名思义，受体测试为阴性，这种类型的乳腺癌尤为积极，对常见的乳腺癌治疗方法反应不佳。

J Bone Miner Res：纤维发育不良增加乳腺癌的风险

乳腺癌是女性中最常见的癌症之一，威胁着全世界女性的生命，关于乳腺癌风险因素的研究比比皆是，最近，发表于《骨骼与矿物质》杂志上的一项研究指出，纤维发育不良(FD)会增加患乳腺癌的风险。

Lancet Oncol：绝经后妇女早期乳腺癌辅助化疗：他莫昔芬+依西美坦vs依西美坦

2017年9月，发表在《Lancet Oncol.》的一项多中心、开放标签、随机化、对照、3期TEAM试验调查了他莫昔芬+依西美坦用于绝经后妇女早期乳腺癌辅助化疗的长期随访（10年）结果。

乳腺癌“全程·全方位”管理模式逐步落地 ——管理重心由“病”到“人”

2017年9月17日，中国乳腺癌全程全方位管理西区首席专家论坛在贵阳顺利召开，来自贵州、新疆、北京、川渝、陕西等地的24位与会专家结合乳腺癌发病特点和就诊模式，共同探讨乳腺癌“全程、全方位”管理模式落地的具体规划，为提升贵州乃至西部地区乳腺癌患者的健康管理水平奠定坚实基础。

CA Cancer J Clin：肥胖与乳腺癌的发病风险及预后：机制及干预措施

近几十年来，肥胖症的发病率迅猛上升，肥胖对健康的影响也日益明显。2014年全世界约有19亿多成年人超重（体重指数[BMI]，25-29.9 kg/m2），其中6亿多人为肥胖者（BMI ≥30 kg/m2）。众所周知，肥胖可增加糖尿病和冠状动脉疾病的发病风险，但是肥胖对癌症的发生、发病率和死亡率的影响却并没有得到充分的重视。肥胖可增加女性乳腺癌的发病风险，特别是绝经后妇女，还可恶化所有年龄段女性的疾

乳腺增生会癌变吗，到底要不要治？每个女人都该知道

近年来，一些女性名人因为乳腺癌英年早逝，使得很多人“谈乳色变”。当一些女性朋友在体检报告上发现“乳腺小叶增生”的字样时，不禁担心疑惑：乳腺小叶增生是怎么回事？我怎么会得这个毛病呢？这个病会不会发展成乳腺癌？需要治疗么？